Not to pump a product. But I have been an investor in the company MannKind for about 1 year. Currently the product is only approved in the USA but eventually Sanofi will have approval for Europe, UK and eventually 120 nations worldwide. The stock has been beat up by shorts. There are 420 Million shares. with the Founder of the company controlling about 55% of the shares. Institutional investors have about 23% of the shares with 22% controlled by folks like me an individual investor. Of the 22% of the shares there is a short interest of 78,000 Shares. So they have kept the price down. It’s a battleground stock but at some time it will really pop if the Inhaled insulin product Afrezza sells. Then again it might not. But Afrezza and its delivery method the Technosphere inhaler is a DISRUPTIVE TECHNOLGY and this innovation will catch on with folks who want to have less needle sticks and able to control mealtime insulin.
The price range of the stock in the last 12 months has been about 3.25 - 11.00 But now the product was FDA approved June 28, 2014, MannKind Partnered with Sanofi on August 12, 2014. Set up the production and distribution channels with Sanofi with Sanofi paying them the initial partnership payment of 150,000,000 November 1, and then two milestone payments of 25,000,000 each since then. The official launch of the product occurred as this article stated on February 3rd.
It will help the new diabetic and type 2 diabetics avoid the needle (not eliminate) and keep their blood sugar in range especially around meal time. I am middle age and fit the target as pre-diabetic who is over 50,overweight and would avoid needles as long as I could. Doctors call this the lost decade. People between 45 & 60 who should be on medication but are avoiding the needle. These are the folks who eventually have to take insulin, but don’t and eventually suffer the consequences of diabetes. Loss of limbs, Kidney disease blindness and other serious complications.
I believe that Afrezza (MannKind) will sell and the founder of the company Al Mann has been behind many medical inventions and medicines. He was the person who developed the Insulin Pump and later sold it to Medtronic. He developed the Cochlear Ear implant. Google the name Al Mann and you will discover why this man is a genius.
The company also has many patents on their deliver device called Technosphere. So the future of other medicines being developed for delivery by Technosphere is there too.
Please do your own due diligence but investigate Mannkind and Afrezza. If you’re an investor always invest with your eyes open as you could win or lose. But if you’re a diabetic this product might really be a game changer with its unique delivery system Technosphere.
Exactly, it is why I keep writing that any diabetic must check with their endo or GP to ask about this. It isn’t for everyone.
Bttt